Published on
April 7, 2026
- 08:03 GMT
Liver Failure: Amgen Continues Marketing Avacopan (Tavneos) in the United States
LOS ANGELES, CA, UNITED STATES, April 7, 2026 /EINPresswire.com/ -- Greg Vigna, MD, JD, a national pharmaceutical injury attorney, states, “Amgen is not removing its drug despite the FDA’s request. Reported complications include acute liver …
Distribution channels:
Business & Economy, Consumer Goods
...
